FDA Postmarket Cybersecurity in 2026
Coordinated vulnerability disclosure, patching legacy devices, and meeting FDA's postmarket cybersecurity expectations after launch.
Once a device is in the field, the cybersecurity work has just begun. Postmarket vulnerability management, coordinated disclosure, patching strategies, and field safety notifications are critical for keeping patients safe and your authorization intact. These episodes cover real-world incident response, working with security researchers, navigating CISA and FDA reporting, and building a postmarket surveillance program that scales.
This page rounds up every FDA Postmarket Cybersecurity conversation we've published in 2026 on The Med Device Cyber Podcast. Each episode pairs an experienced practitioner - a regulator, a startup founder, a security researcher, or a quality lead - with our hosts, who've personally led FDA premarket and postmarket cybersecurity submissions for connected medical devices. The result is a working library of frameworks, war stories, and reviewer-tested patterns you can apply to your own 510(k), De Novo, or PMA program.
Use the 2026 archive below to get a sense of how fda postmarket expectations are evolving this year - what the FDA is asking for in deficiency letters, which engineering practices the field is converging on, and where reasonable people still disagree. If you want a longer-running view, browse the full FDA Postmarket Cybersecurity topic page for every episode we've ever published on the subject, or jump to the complete 2026 catalog to see what else aired alongside these episodes.
